Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02427243 · ClinicalTrials.gov registry record · Phase 1
A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT02427243 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 60 participants.
The verdict
NCT02427243, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
To assess the relative bioavailability and tolerability of two different formulations of crenezumab in approximately 60 healthy volunteers.
Interventions
- DRUG Crenezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2015-04 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02427243
The ClinicalTrials.gov registry entry for NCT02427243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Crenezumab is the first listed.
NCT02427243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02427243 about?
NCT02427243 is a clinical study titled "A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose". To assess the relative bioavailability and tolerability of two different formulations of crenezumab in approximately 60 healthy volunteers.
What is the current status of trial NCT02427243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2015-04. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02427243?
The interventions under investigation include: Crenezumab (DRUG).
Who is sponsoring clinical trial NCT02427243?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.